Biogen | BIIB - Selling And Administration Expenses


Biogen reported $709.7M in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.63B 54M Jun/2026
Acadia Pharmaceuticals USD 148.57M 12.22M Jun/2026
ALKERMES USD 196.64M 67.96M Jun/2026
Amgen USD 1.72B 134M Jun/2026
Bayer EUR 3.96B 267M Jun/2026
Biogen USD 709.7M 155.4M Jun/2026
BioMarin Pharmaceutical USD 395.55M 137.27M Jun/2026
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
Eli Lilly USD 3.43B 496M Jun/2026
Gilead Sciences USD 1.52B 70M Jun/2026
Incyte USD 351.73M 23.64M Jun/2026
Merck USD 2.89B 219M Jun/2026
Moderna USD 216M 43M Jun/2026
Neurocrine Biosciences USD 383.1M 64.6M Jun/2026
Novartis USD 3.24B 101M Jun/2026
Pfizer USD 3.41B 496M Jun/2026
PTC Therapeutics USD 80.63M 6.74M Jun/2026
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sanofi EUR 2.63B 307M Jun/2026
Sanofi EUR 2.49B 252M Mar/2026
Sarepta Therapeutics USD 107.6M 53.57M Jun/2026
Teva Pharmaceutical Industries USD 1.03B 34M Jun/2026
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
United Therapeutics USD 206.7M 50.1M Jun/2026
Vertex Pharmaceuticals USD 582.2M 88.5M Jun/2026